The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations

Introduction: EGFR exon 20 insertion mutations account for 5% to 10% of EGFR-mutated NSCLC. CLN-081 (formerly known as TAS6417), a novel covalent EGFR tyrosine kinase inhibitor, exhibits pan-mutation selective efficacy, including exon 20 insertions, in the clinical setting. Nevertheless, some patien...

Полное описание

Библиографические подробности

Главные авторы:	Yosuke Kagawa, MD, Takuma Hayashida, MS, Jie Liu, BS, Shunta Mori, MD, Hiroki Izumi, MD, PhD, Shogo Kumagai, MD, PhD, Hibiki Udagawa, MD, PhD, Noboru Hattori, MD, PhD, Koichi Goto, MD, PhD, Susumu S. Kobayashi, MD, PhD
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2023-03-01
Серии:	JTO Clinical and Research Reports
Предметы:	Non–small cell lung cancer EGFR CLN-081 Resistant mechanism C797S
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2666364323000012
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!